Machine Learning for Survival Analysis: A New Approach

D. Dooling P. Green A. Kim D. Scroggin L. Stevens J. Webster

Innovative Oncology Business Solutions, 4901 Lang Ave NE, Albuquerque, NM 87109, USA

E-mail: ddooling@innovativeobs.com, pgreen@innovativeobs.com, akim@innovativeobs.com, dscroggin@innovativeobs.com, lstevens@innovativeobs.com

ABSTRACT: We have applied a little-known data transformation on subsets of the Surveillance, Epidemiology, and End Results (SEER) publically available data of the National Cancer Institute (NCI) to make it suitable input to standard machine learning classifiers. This transformation properly treats the right-censored data in the SEER data and the resulting Random Forest and Multi-Layer Perceptron models predict full survival curves. Treating the 6, 12, and 60 months points of the resulting survival curves as 3 binary classifiers, the 18 resulting classifiers have AUC values ranging from .765 to .885. Further evidence that the models have generalized well from the training data is provided by the extremely high levels of agreement between the random forest and neural network models predictions on the 6, 12, and 60 month binary classifiers.

1 Introduction and Background 2 2 Methodology 4 2.1 Data acquisition 4 2.2 Data preparation and preprocessing 4 2.3 Colon Cancer Data 6 2.4 Lung Cancer Data 7 2.5 Breast Cancer Data 8 3 Machine Learning Survival Analysis with Censored Data 10 3.1 Survival Analysis 11 3.2 Transformation of Censored Data for Machine Learning 14 4 Prediction Models 17 4.1 Training and Test Partitions 18 4.2 Decision Trees and Random Forests 19 4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32	C	ontents	
2.1 Data acquisition 4 2.2 Data preparation and preprocessing 4 2.3 Colon Cancer Data 6 2.4 Lung Cancer Data 7 2.5 Breast Cancer Data 8 3 Machine Learning Survival Analysis with Censored Data 10 3.1 Survival Analysis 11 3.2 Transformation of Censored Data for Machine Learning 14 4 Prediction Models 17 4.1 Training and Test Partitions 18 4.2 Decision Trees and Random Forests 19 4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32	1	Introduction and Background	2
2.2 Data preparation and preprocessing 4 2.3 Colon Cancer Data 6 2.4 Lung Cancer Data 7 2.5 Breast Cancer Data 8 3 Machine Learning Survival Analysis with Censored Data 10 3.1 Survival Analysis 11 3.2 Transformation of Censored Data for Machine Learning 14 4 Prediction Models 17 4.1 Training and Test Partitions 18 4.2 Decision Trees and Random Forests 19 4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Archi	2	Methodology	4
2.3 Colon Cancer Data 6 2.4 Lung Cancer Data 7 2.5 Breast Cancer Data 8 3 Machine Learning Survival Analysis with Censored Data 10 3.1 Survival Analysis 11 3.2 Transformation of Censored Data for Machine Learning 14 4 Prediction Models 17 4.1 Training and Test Partitions 18 4.2 Decision Trees and Random Forests 19 4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 32 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 <td< td=""><td></td><td>2.1 Data acquisition</td><td>4</td></td<>		2.1 Data acquisition	4
2.4 Lung Cancer Data 7 2.5 Breast Cancer Data 8 3 Machine Learning Survival Analysis with Censored Data 10 3.1 Survival Analysis 11 3.2 Transformation of Censored Data for Machine Learning 14 4 Prediction Models 17 4.1 Training and Test Partitions 18 4.2 Decision Trees and Random Forests 19 4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2		2.2 Data preparation and preprocessing	4
2.5 Breast Cancer Data 8 3 Machine Learning Survival Analysis with Censored Data 10 3.1 Survival Analysis 11 3.2 Transformation of Censored Data for Machine Learning 14 4 Prediction Models 17 4.1 Training and Test Partitions 18 4.2 Decision Trees and Random Forests 19 4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3		2.3 Colon Cancer Data	6
3 Machine Learning Survival Analysis with Censored Data 10 3.1 Survival Analysis 11 3.2 Transformation of Censored Data for Machine Learning 14 4 Prediction Models 17 4.1 Training and Test Partitions 18 4.2 Decision Trees and Random Forests 19 4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33		2.4 Lung Cancer Data	7
3.1 Survival Analysis 11 3.2 Transformation of Censored Data for Machine Learning 14 4 Prediction Models 17 4.1 Training and Test Partitions 18 4.2 Decision Trees and Random Forests 19 4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33 30 33		2.5 Breast Cancer Data	8
3.2 Transformation of Censored Data for Machine Learning 14 4 Prediction Models 17 4.1 Training and Test Partitions 18 4.2 Decision Trees and Random Forests 19 4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33 30 33	3	Machine Learning Survival Analysis with Censored Data	10
4 Prediction Models 17 4.1 Training and Test Partitions 18 4.2 Decision Trees and Random Forests 19 4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33		3.1 Survival Analysis	11
4.1 Training and Test Partitions 18 4.2 Decision Trees and Random Forests 19 4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33		3.2 Transformation of Censored Data for Machine Learning	14
4.2 Decision Trees and Random Forests 19 4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33	4	Prediction Models	17
4.3 MLP Neural Networks 20 5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33		4.1 Training and Test Partitions	18
5 Results 21 5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33		4.2 Decision Trees and Random Forests	19
5.1 Performance Metrics 21 5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33		4.3 MLP Neural Networks	20
5.2 Model Agreement 21 6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33	5	Results	21
6 Survival Curve Prediction Apps 22 7 Further Directions 23 A Selected Features A.1 Colon Cancer Feature Selection A.2 Lung Cancer Feature Selection B reast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33		5.1 Performance Metrics	21
7 Further Directions 23 A Selected Features 24 A.1 Colon Cancer Feature Selection 24 A.2 Lung Cancer Feature Selection 27 A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation 31 C Model Architecture and Python Code 32 C.1 Breast Random Forest Model 32 C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33 C.5 Colon Cancer Neural Network Model 33		5.2 Model Agreement	21
A Selected Features A.1 Colon Cancer Feature Selection A.2 Lung Cancer Feature Selection A.3 Breast Cancer Feature Selection B Pseudocode for the Data Transformation C Model Architecture and Python Code C.1 Breast Random Forest Model C.2 Colon Random Forest Model C.3 Lung Random Forest Model C.4 Breast Neural Network Model C.5 Colon Cancer Neural Network Model 33 34 35 36 36 37 38 38 39 39 30 30 30 30 30 30 30 30 30 30 30 30 30	6	Survival Curve Prediction Apps	22
A.1 Colon Cancer Feature Selection A.2 Lung Cancer Feature Selection A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation C Model Architecture and Python Code C.1 Breast Random Forest Model C.2 Colon Random Forest Model C.3 Lung Random Forest Model C.4 Breast Neural Network Model C.5 Colon Cancer Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33 34 35 36 37 38 38 39 30 30 30 30 30 30 30 30 30	7	Further Directions	23
A.2 Lung Cancer Feature Selection A.3 Breast Cancer Feature Selection 29 B Pseudocode for the Data Transformation C Model Architecture and Python Code C.1 Breast Random Forest Model C.2 Colon Random Forest Model C.3 Lung Random Forest Model C.4 Breast Neural Network Model C.5 Colon Cancer Neural Network Model 32 33 34 35 36 37 38 39 30 30 30 30 31 30 31 31 31 32 32 33 34 35 36 37 38 38 39 30 30 30 30 30 30 30 30 30	\mathbf{A}	Selected Features	24
A.3 Breast Cancer Feature Selection B Pseudocode for the Data Transformation C Model Architecture and Python Code C.1 Breast Random Forest Model C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33 36 37 38 38 39 30 30 31 31 32 32 32 33 33		A.1 Colon Cancer Feature Selection	24
B Pseudocode for the Data Transformation C Model Architecture and Python Code C.1 Breast Random Forest Model C.2 Colon Random Forest Model 32 C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33 33		A.2 Lung Cancer Feature Selection	27
C Model Architecture and Python Code C.1 Breast Random Forest Model C.2 Colon Random Forest Model C.3 Lung Random Forest Model C.4 Breast Neural Network Model C.5 Colon Cancer Neural Network Model 33 33 33		A.3 Breast Cancer Feature Selection	29
 C.1 Breast Random Forest Model C.2 Colon Random Forest Model C.3 Lung Random Forest Model C.4 Breast Neural Network Model C.5 Colon Cancer Neural Network Model 33 	В	Pseudocode for the Data Transformation	31
 C.2 Colon Random Forest Model C.3 Lung Random Forest Model C.4 Breast Neural Network Model C.5 Colon Cancer Neural Network Model 33 	\mathbf{C}	Model Architecture and Python Code	32
C.3 Lung Random Forest Model 32 C.4 Breast Neural Network Model 32 C.5 Colon Cancer Neural Network Model 33		C.1 Breast Random Forest Model	32
C.4 Breast Neural Network Model C.5 Colon Cancer Neural Network Model 32 33		C.2 Colon Random Forest Model	32
C.5 Colon Cancer Neural Network Model 33		C.3 Lung Random Forest Model	32
		C.4 Breast Neural Network Model	32
C.6 Lung Cancer Neural Network Model 34		C.5 Colon Cancer Neural Network Model	33
		C.6 Lung Cancer Neural Network Model	34

1 Introduction and Background

Oppurtunties are emerging in many indutries today to develop and deploy services that cater to individual needs and preferences. Music afficianados can create their own radio stations tailored to their individual tastes from Pandora¹, bibliophiles can receive highly trustworthy book recommendations from goodreads.com², and Google will provide directions between any two points, giving options such as mode as transportation and warnings of delays in realtime.³ These individualized services share many common features. In particular, they leverage large databases of aggregated information to learn and extract information relevant to individuals. Extracting actionable information from data is changing the fabric of modern business. A class of techniques that transforms data into actionable information goes by the name of Machine Learning [1]. Machine Learning has recently become a popular method to answer questions and solve problems that are too complex to solve via traditional methods.

The objective of this study is to show how machine learning methods can be trained with data in cancer registries to produce personalized survival prognosis curves. Traditionally, cancer survival curves have been estimated using Kaplan-Meier methods [2]. Kaplan-Meier methodology also uses large datasets to make predictions, but the resulting information is not personal; the resulting curves are summaries for a population and not necessarily relevant or particularly accurate for any given individual. The methods described below also take full advantage of all relevant aggregate information, but are able to provide personalized survival curves relevant to individual subjects. The situation is analgous to consulting the New York Time's bestseller list for your next book⁴, or taking recommendations from your personalized Amazon "recommended for you" service. This capability of providing individualized survival curve prognosis is a direct result of the recent advances in computing power and machine learning algorithms, and similar methodology is becoming commonplace in many industries. These techniques are slowly infiltrating the healthcare industry, in spite of some of the data aggregation challenges posed by the Health Insurance Portability and Accountability Act (HIPPA) of 1996.

The Surveillance, Epidemiolgy, and End Results (SEER) Program of the National Cancer Institute (NCI) has been collecting data because intuitively researchers feel confident that this data will eventually allow researches to detect information crucial to patients and providers including the relationships between the types of data collected (demographic as well as staging information, treatment and disease characteristics) and the survival outcomes. Though this relationship evades capture by traditional methods, it is possible to surface it with the two machine learning techniques known as Random Forests and Neural Networks. These two methods produce very similar results when applied to the SEER

¹Pandora Internet Radio - Listen to Free Music You'll Love, http://www.pandora.com/ (accessed 27 Jan 2016)

²Share Book Recommendations With Your Friends, Join Book Clubs, Answer Trivia, https://www.goodreads.com/ (accessed 27 Jan 2016)

³Google Maps, https://goo.gl/1D7Jwf (accessed 27 Jan 2016)

⁴http://www.nytimes.com/best-sellers-books/

dataset, and are based on two almost diametrically opposed learning philosophies, which lends confidence in the validity of the results.

The Surveillance, Epidemiolgy, and End Results (SEER) Program of the National Cancer Institute (NCI) is the most recognized authoritative source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the US population.

Quoting directly from the SEER website [3]:

The SEER program registries routinely collect data on patient demographics, primary tumor site, tumor morphology and stage at diagnosis, first course of treatment, and follow-up for vital status. This program is the only comprehensive source of population-based information in the United States that includes stage of cancer at the time of diagnosis and patient survival data. The mortality data reported by SEER are provided by the National Center for Health Statistics. The population data used in calculating cancer rates is obtained periodically from the Census Bureau. Updated annually and provided as a public service in print and electronic formats, SEER data are used by thousands of researchers, clinicians, public health officials, legislators, policymakers, community groups, and the public.

One characterstic of the SEER data and that is shared by many datasets in the medical field goes by the name of "censored data." Observations are labeled censored when the survival time information is incomplete. The SEER data contains the number of months each patient survived, as well as an indicator variable showing whether or not the patient is still alive at the end of the data collection period. Methods to deal effectively with this kind of "right-censored data" include Kaplan-Meier curves and Cox Proportional Hazard models [2]. The Kaplan-Meier techniques only give estimates for cohorts of patients and are not applicable for predicting the surival curve for a single patient, and the Cox Proportional Hazard models require a fairly restrictive set of assumptions to be satisifed in order to yield reliable results. The Cox Proportional Hazard models are not able to capture the nonlinear relationships between the given data fields that go into making predictions; they can only capture the first-order linear relationships.

Previous work applying machine learning methods to subsets of the SEER data include creative attempts to deal with the problems presented by "right-censored data." Shin et al. [4] use semi-supervised learning techniques to predict 5 year survival, essentially imputing values for SEER records where the survival months infomation is censored at a value less than 5 years. Zolbanin et al. [5] investigate the effects of comordbidities; i.e., patients with two different cancer diagnosises, but their treatment of the censored data underestimates the survival probabilities. All records representing patients who survived at least 60 months as well as all those who died earlier than 60 months were considered, but patients alive prior to 60 months but censored out of the study before 60 months were not included. This treatment biases the data and the predictions, leading to overly pessimistic survival probabilities predicted by the models.

IOBS has applied a little-known technique to transform the SEER data to make it amenable to more powerful machine learning methods. The essential idea is to recast the problem to an appropriate discrete classification problem instead of a regression problem (predicting survival months). Treating months after diagnosis as just another discrete feature, the SEER data (or any other right-censored data) can be transformed to make predictions for the hazard function (probability of dying in the next month, given that the patient has not yet died). The full survival function can then be derived from the hazard function. Details of this transformation can be found in this blog post [6] and are presented in section (3.2).

2 Methodology

2.1 Data acquisition

We used the publically available 1973-2012 SEER incidence data files corresponding to colon, breast and lung cancer contained in the following list. SEER requires that researchers submit a request for the data, which includes an agreement form. Detailed documentation explaining the contents of both the incidence data files used in this study as well as a data dictionary for the 1973-2012 SEER incidence data files are available without the need to register or submit a data request [7].

- incidence\yr1973 2012.seer9\COLRECT.txt
- incidence\yr1973 2012.seer9\BREAST.txt
- incidence\yr1973 2012.seer9\RESPIR.txt
- incidence $\yr1992_2012.sj_la_rg_ak\COLRECT.txt$
- incidence\yr1992 2012.sj la rg ak\BREAST.txt
- incidence\yr1992 2012.sj la rg ak\RESPIR.txt
- incidence\yr2000 2012.ca ky lo nj ga\COLRECT.txt
- incidence\yr2000 2012.ca ky lo nj ga\BREAST.txt
- incidence\yr2000 2012.ca ky lo nj ga\RESPIR.txt
- incidence\yr2005.lo 2nd half\COLRECT.txt
- incidence\yr2005.lo 2nd half\BREAST.txt
- incidence\yr2005.lo 2nd half\RESPIR.txt

2.2 Data preparation and preprocessing

A great deal of data munging is necessary before using these SEER incidence files as input into machine learning algorithms. A preprocessing step common to each of the three cancer types studied involves the STATE-COUNTY RECODE variable. The STATE-COUNTY RECODE field is a state-county combination where the first two characters represent the state FIPS code and the last three digits represent the FIPS county code. This particular field illustrates an important characteristic of machine learning, that between categorical features and numeric features. All input into a machine learning algorithm must be numeric, but real numbers carry with them the usually extremely useful property known as the well-ordering property. But if one is tasked with encoding a categorical feature into suitable

Code	Description
1	Male
2	Female

Table 1. Encoding of gender in the SEER incidence files. These types of categorical variables need to be transformed via one-hot-encoding.

numeric format for machine learning, it is necessary to do so in a way that removes the well-ordering property [8].

As a simple example of how to correctly treat categorical variables in a machine learning context, consider the SEER variable SEX. This variable is encoded with a numeric 1 for males and a numeric 2 for females as shown in Table (1). Values such as "Male" and "Female" encoded as numbers are dangerous because if not handled properly, they can generate bogus results [9]. The proper way to transform the SEER SEX variable is to create two additional variables: sex_Male and sex_Female, and then to eliminate the variables SEX and sex_Male (keeping both of the variables sex_Male and sex_Female is a redundant representation). For example,

and

The procedure outlined in Equations (2.1, 2.2) and known as one-hot encoding needs to be applied to all of the nominal categorical variables in the SEER data that we wish to include in our predictive models. In particular, in order to include the geophgraphical information contained in the SEER categorical variable STATE-COUNTY RECODE, it becomes necessary to create a new feature variable for each of the distinct (state,county) pairs in the data. In the United States, there are approximately 3,000 counties. Clearly, transforming the STATE-COUNTY RECODE data representation into distinct (state_county) columns will explode the data to become wider than is optimal for machine learning. Adding extra columns to your dataset, making it wider, requires more data rows (making it taller) in order for machine learning algorithms to effectively learn [8]. Because one-hot coding STATE-COUNTY RECODE would cause such drastic shape changes in our data, we wish to avoid doing so. Fortunately, this variable, though given as a categorical variable, is actually an ordinal variable. There is an ordering among the (state_county) columns, namely longitude, latitude, and elevation. We can transform the data in STATE-COUNTY RECODE into three new numerical columns: lat, lng, and elevation.

STATE-COUNTY RECODE	address	elevation	lat	lng
35001	Bernalillo+county+NM	5207.579772	35.017785	-106.629130
35003	${\tt Catron+county+NM}$	8089.242628	34.151517	-108.427605
35005	${\tt Chaves+county+NM}$	3559.931671	33.475739	-104.472330
35006	${\it Cibola+county+NM}$	6443.415570	35.094756	-107.858387
35007	$_{\rm Colfax+county+NM}$	6147.749089	36.579976	-104.472330

Table 2. Example of the transformation of STATE-COUNTY RECODE to elevation, lat, and lng.

For example, Table (2) shows how five entries of STATE-COUNTY RECODE corresponding to counties within New Mexico can be represented by the elevation, lat, and lng features.

It is a simple exercise to construct the full lookup table from the SEER STATE-COUNTY RECODE variable to the corresponding three values elevation, lat, and lng. We use the publically available dafafile from the United States Census Bureau [10] to map the state FIPS and county FIPS codes to query strings like those in the address field in Table (2). It is then possible to programmatically query the Google Maps Geocoding API for the latitude and longitude [11], and the Google Maps Elevation API for the corresponding elevation [12]. An added benefit of this shift from the single categorical variable STATE-COUNTY RECODE to the three continuous numerical variables lat, lng, and elevation is that input into the web applications described in section (6) are not restricted to the states and counties coverered in the SEER registries; in fact, the input to the models can be any address you would enter into Google Maps and calls to the Google Maps Geocoding API and the Google Maps Elevation API provide the conversion from the address string to the input variables lat, lng, and elevation. The full lookup table analogous to Table (2) is available from a GitHub repository containing supplemental information for this study [13].

2.3 Colon Cancer Data

In this section we describe the data processing steps that were specific to the colon cancer model development. The four COLRECT.txt files were imported into a pandas DataFrame object. This data was then filtered according to the conditions in Table 3.

The following categorical features were one-hot encoded as described in section 2.2:

- SEX,
- MARITAL STATUS AT DX,
- RACE/ETHNICITY,
- SPANISH/HISPANIC ORIGIN,
- GRADE ,
- PRIMARY SITE,

Column	Filter
SEQUENCE NUMBER-CENTRAL	eq "Unspecified"
AGE AT DIAGNOSIS	eq "Unknown age"
BIRTHDATE-YEAR	eq "Unknown year of birth"
YEAR OF DIAGNOSIS	≥ 2004
SURVIVAL MONTHS FLAG	= "1"
CS TUMOR SIZE EXT/EVAL	≠ ""
CS TUMOR SIZE	$\neq 999$
SEER RECORD NUMBER	=1
PRIMARY SITE	= "LARGE INTESTINE, (EXCL. APPENDIX)"
SEQUENCE NUMBER-CENTRAL	=0

Table 3. Filters applied to the Colon Cancer data.

- LATERALITY ,
- SEER HISTORIC STAGE A,
- HISTOLOGY RECODE-BROAD GROUPINGS,
- MONTH OF DIAGNOSIS,
- VITAL STATUS RECODE.

The STATE-COUNTY RECODE variable was dropped and replaced with the elevation, lat, and lng variables as illustrated in Table 2.

With just the above data preparation, it is possible to construct traditional Kaplan-Meier estimates of the survival curves for the colon cancer population represented by this subset of the data. After the above one-hot encoding procedure, the new variable vital_status_recode_Dead indicates that the patient is deceased if this variable = 1, or else that the patient's record is right-censored if this variable = 0. SURVIVAL MONTHS and vital_status_recode_Dead are all that is needed to construct the Kaplan-Meier estimate shown in Figure (1).

2.4 Lung Cancer Data

In this section we describe the data processing steps that were specific to the lung cancer model development. The four RESPIR.txt files were imported into a pandas DataFrame object. This data was then filtered according to the conditions in Table 4. The same list of categorical features as in the colon cancer case were then one-hot encoded.

With just the above data preparation, it is possible to construct traditional Kaplan-Meier estimates of the survival curves for the colon cancer population represented by this subset of the data. After the above one-hot encoding procedure, the new variable vital_status_recode_Dead indicates that the patient is deceased if this variable = 1, or else that the patient's record is right-censored if this variable = 0. SURVIVAL MONTHS and vital_status_recode_Dead are all that is needed to construct the Kaplan-Meier estimate shown in Figure (2).




Figure 1. Traditional Kaplan-Meier estimate of the survival curve for all colon cancer patients. Fitted with 113072 observations, 71804 censored.

Column	Filter
SEQUENCE NUMBER-CENTRAL	$ \neq$ "Unspecified"
AGE AT DIAGNOSIS	eq "Unknown age"
BIRTHDATE-YEAR	eq "Unknown year of birth"
YEAR OF DIAGNOSIS	≥ 2004
SURVIVAL MONTHS FLAG	= "1"
CS TUMOR SIZE EXT/EVAL	≠ ""
CS TUMOR SIZE	$\neq 999$
SEER RECORD NUMBER	=1
PRIMARY SITE	= "LUNG & BRONCHUS"
SEQUENCE NUMBER-CENTRAL	=0

Table 4. Filters applied to the Lung Cancer data.

2.5 Breast Cancer Data

In this section we describe the data processing steps that were specific to the lung cancer model development. The four BREAST.txt files were imported into a pandas DataFrame object. This data was then filtered according to the conditions in Table 5. The same list of categorical features as in the colon cancer case were then one-hot encoded.




Figure 2. Traditional Kaplan-Meier estimate of the survival curve for all lung cancer patients. Fitted with 177089 observatins, 47409 censored.

Column	Filter
SEQUENCE NUMBER-CENTRAL	eq "Unspecified"
AGE AT DIAGNOSIS	eq "Unknown age"
BIRTHDATE-YEAR	eq "Unknown year of birth"
YEAR OF DIAGNOSIS	≥ 2004
SURVIVAL MONTHS FLAG	= "1"
CS TUMOR SIZE EXT/EVAL	≠ " "
CS TUMOR SIZE	$\neq 999$
SEER RECORD NUMBER	=1
SEQUENCE NUMBER-CENTRAL	=0

Table 5. Filters applied to the Breast Cancer data.

With just the above data preparation, it is possible to construct traditional Kaplan-Meier estimates of the survival curves for the colon cancer population represented by this subset of the data. After the above one-hot encoding procedure, the new variable vital_status_recode_Dead indicates that the patient is deceased if this variable = 1, or else that the patient's record is right-censored if this variable = 0. SURVIVAL MONTHS and vital_status_recode_Dead are all that is needed to construct the Kaplan-Meier estimate




Figure 3. Traditional Kaplan-Meier estimate of the survival curve for all breast cancer patients. Fitted with 329949 observatins, 292279 censored.

shown in Figure (3).

Before applying machine learning models trained with these data sets, we review in section (3) the sailent features of survival analysis and censored data. We then describe in detail a method that takes full advantage of all the data, including the right-censored data, and which involves a simple and intuitive transformation, culminating in the full set of features and target variables listed in sections (A.1, A.2, A.3).

3 Machine Learning Survival Analysis with Censored Data

The above Kaplan-Meier estimates of the survival curves for colon (Figure (1), lung (Figure (2), and breast cancer (Figure (3) are constructed from the full population of cancer patients in the respective datasets. An unsatisfactory consequence is that these estimates are highly course-grained, and not very meaningful to an indivual. Patients with very disparate characteristics are given the same prognosis by these Kaplan-Meier survival curve estimates. Therefore it is desirable to find robust predictors for survival curves of individual subjects where the input is an individual record as opposed to a population. In section (3.1) we briefly review the pertinent features of survival analyis, before presenting in section (3.2) the data transformation that allows for machine learning to be applied to censored data.

3.1 Survival Analysis

Survival analysis pertains to data containing survival times, which are *intervals* between certain kinds of events, e.g.; cancer diagnosis date and expiry date. These intervals are often affected by a kind of "partial missingness" called *censoring*. Censored data must be analyzed in a special way to avoid biased estimates and bogus conclusions. Special methods have been developed long ago to analyze censored data properly.

With survival data, including the SEER data considered in this study, you may not know the exact time of death for some subjects. Some of the SEER subjects are still alive at the time of the latest SEER data release. When the VITAL STATUS RECODE variable indicates that the subject is still alive, the SURVIVAL MONTHS variable is only a lower bound on the true number of survival months; this is called the *date of last contact* mode of censoring. You know that each subject either died on a certain date or was definitely alive up to some last-seen date (and you don't know how far beyond that date he or she may ultimately have lived). The latter situation is called a *censored* observation.

Statisticians have developed some traditional techniques to utilize the partial information contained in censored observations: the life-table method and the Kaplan-Meier method. Both of these methods make use of the partial information to provide unbiased estimates of the two fundamental concepts: - hazard and survival, both of which are functions of time:

- The hazard rate $\lambda(t)$ is the probability of dying in the next small interval of time, assuming that the subject is alive right now.
- The survival rate S(t) is the probability of living for a certain amount of time after some starting point.

Incorrect treatment of survival data still seen in practice, and leading to biased results, include simply excluding all subjects with a censored survival time from any survival analysis, and *imputing* (replacing) the censored (last-seen) date with some reasonable value. Both of these techniques destroy the partial information contained in the censored observations and nullify the validity of the resulting estimates for the hazard rate and survival rate [2].

To estimate survival and hazard rates in a population from a set of observed survival times, some of which are censored, you must combine the information from censored and uncensored observations properly. You have to think of the process in terms of a series of small slices of time, and think of the probability of making it through each time slice, assuming that the subject is alive at the start of that slice. The cumulative survival probability can then be obtained by successively multiplying all these individual time-slice survival probabilities together. For example, to survive three years, first the subject has to make it through Year 1, then she has to make it through Year 2, and then she has to make it through Year 3. The probability of making it through all three years is the product of the probabilities of making it through Year 1, Year 2, and Year 3. These calculations can be laid out very systematically in a life table, sometimes called an actuarial life table because

	Survival Time (Years)	Censored Status
0	0.75	1
1	6.10	1
2	7.00	0
3	2.40	1
4	0.50	0
5	4.50	1
6	3.50	0
7	5.80	0
8	2.30	1
9	5.20	1

Table 6. Example data to illustate traditional Survival Analysis.

of its early use by insurance comparies. The calculations involce only addition, subtraction, multiplication, and division and are simple enough to do by hand.

To create a life table from your survival-time data, first break the entire range of survival times into convenient time slices (months, quarters, or years, depending on the time scale of the event you're studying). You should try to have at least five slices, otherwise, your survival and hazard estimates will be too coarse to show any useful features. Having very fine slices doesn't hurt the calculations, although the table will have more rows and may become unweildly. Next, count how many people died during each slice and how many were *censored* (that is, last seen alive during that slice, either because they became lost to follow-up or were still alive at the end of the study). For the survival times shown in Table (6), a natural choice would be to use seven one-year time slices.

Next, count how many people died during each slice and how many were *censored* (that is, last seen alive during that slice, either because they became lost to follow-up or were still alive at the end of the study). From Table (6) you see that

- During the first year after surgery, one subjects died (#0) and one subject was censored (#4)
- During the second year, nothing happened (no deaths, no censoring)
- During the third year, two subjects died (#8 and #3)
- During the fourth year, one subject was censored (#6)
- During the fifth year, one subject died (#5)
- During the sixth year, one subject died (#9) one subject was censored (#7)
- During the seventh year, one subjectdied (#1) and one was censored (#2)

To construct a lifetable, one proceeds as follows:

• Enter the total number of subjects alive at the start into column **Alive at Start**, in the **0-1** yr row

	Died	Censored	Alive at Start	At Risk	Prob of Dying	Prob of Surviving	Cum Survival
0-1 yr	1	1	10	9.5	0.105263	0.894737	0.894737
1-2 yr	0	0	8	8.0	0.000000	1.000000	0.894737
2-3 yr	2	0	8	8.0	0.250000	0.750000	0.671053
3-4 yr	0	1	6	5.5	0.000000	1.000000	0.671053
4-5 yr	1	0	5	5.0	0.200000	0.800000	0.536842
5-6 yr	1	1	4	3.5	0.285714	0.714286	0.383459
6-7 yr	1	1	2	1.5	0.666667	0.333333	0.127820

Table 7. Lifetable corresponding to the example data in Table (6).

- Enter the counts of people who died within each time slice into column Died
- Enter the counts of people who were censored during each time slice into Censored
- The column **At Risk** shows the number of subjects known to be alive at the start of each year after surgery. This is equal to the number of subjects alive at the start of the preceding year minus the number of subjects who died (**Died**) or were censored (**Censored**) during the preceding year.
- The Column At Risk shows the number of subjects "at risk for dying" during each year. You may guess that this is the number of people alive at the start of the interval, but there's one minor correction. (COMPLETELY DISAGREE WITH THIS; A WEAKNESS OF THE METHOD) If any people were censured during that year, then they weren't really "available to die" (to use an awful expression) for the entire year. If you don't know exactly when, during that year, they became censored, then it's reasonable to "split the difference" and consider them at risk for aonly half the year. So the number at risk can be estimated as the number alive at the start of the year, minus one-half of the number who became censored during that year. (ONLY MAKES SENSE FOR LOST TO FOLLOW UP).
- The column **Prob of Dying** shows the probability of dying during each interval, assuming the subject has survived up to the start of that interval. This is simply the number of people who died divided by the number of people at risk during each interval.
- The column **Prob of Surviving** shows the probability of surviving during each interval, assuming the subject has survived up to the start of that interval. Surviving means not dying, so the probability of surviving is simply 1 the probability of dying.
- The column **Cum Survival** shows the cumulative probability of surviving from the time of the operation all the way through the end of this time slice. To survive from the time of the operation through the end of any given year (year N), the subject must survive each of the years from Year 1 through Year N. Because surviving each year is an independent accomplishment, the probability of surviving all N of the years is the product of the individual years' probabilities.

	Censored Status	Survival Times	Alive at Start	Prob of Dying	Prob of Surv	Cum Survival
4	0	0.50	10	0.000000	1.000000	1.000000
0	1	0.75	9	0.111111	0.888889	0.888889
8	1	2.30	8	0.125000	0.875000	0.777778
3	1	2.40	7	0.142857	0.857143	0.666667
6	0	3.50	6	0.000000	1.000000	0.666667
5	1	4.50	5	0.200000	0.800000	0.533333
9	1	5.20	4	0.250000	0.750000	0.400000
7	0	5.80	3	0.000000	1.000000	0.400000
1	1	6.10	2	0.500000	0.500000	0.200000
2	0	7.00	1	0.000000	1.000000	0.200000

Table 8. Kaplan-Meier table corresponding to the example data in Table (6).

The sample hazard and survival values obtained from a life table are only sample estimates (in this example, at 1-year time slices) of the true population hazard and survival functions. The hazard rate obtained from a life table is equal to the probability of dying during each time slice (column **Prob of Dying**) divided by the width of the slice, so the hazard rate for the first year would be expressed as .105 per year, or 10.5 percent per year. The cumulative survival probability in column **Cum Survival**, is the probability of surviving from the operation date through to the end of the interval. It has no units, and it can be expressed as a fraction or as a percentage.

Using very narrow time slices doesn't hurt life-table calculations. In fact, you can define slices so narrow that each subject's survival time falls within its own private little slice. With N subjects, N rows would have one subject each; all the rest of the rows would be empty. And because empty rows don't affect the life-table calculations, you can delete them entirely, leaving a table with only N rows, one for each subject. (If you happen to have two or more subjects with exactly the same survival or censoring time, it's okay to put each of the subjects in a separate row). The life-table calculations work fine with only one subject per row and produce what's called Kaplan-Meier (K-M) Survival estimates. You can think of the K-M method as a very fine-grained life table or a life table as a grouped K-M calculation.

The Kaplan-Meier survival estimate corresponding to the data given in Table (6) is shown in Table (8).

3.2 Transformation of Censored Data for Machine Learning

In this section we describe an inuitive way to transform right-censored data appropriately so that it may be used as input to machine learning algorithms that learn the hazard fuction described in section 3.1. The full details of this transformation, and a large inspiration for this study, can be flound in this blog post [6].

The overall philosophy of the Kaplan-Meier estimate of the survival curve for a population differs fundamentally from the methods described below and used in this study. The Kaplan-Meier estimate of the survival curve is given by

$$\hat{S}(t) = \prod_{t_i < t} \frac{n_i - d_i}{n_i} \tag{3.1}$$

where d_i are the number of death events at time t and n_t is the number of subjects at risk of death just prior to time t. Equation 3.1 uses the entire data set to arrive at an estimate of the entire population survival curve. In contrast, the method described below uses the entire data set to learn a model so as to predict hazard and survival curves for all of the individual records in the data set.

The key observation is to note that the hazard function can be readily learned via machine learning methods. It can be rewritten as

$$\lambda(\mathbf{X}, t) = P(Y = t | Y \ge t, \mathbf{X}),\tag{3.2}$$

the probability that, if someone has survived up until month t, they will die in that month. where ${\bf X}$ represents all of the data for that particular record, and in our case Y represents the true, uncensored number of survival months of the patient. What is actually provided in the SEER data is the related variable SURVIVAL MONTHS T (how long each subject was in the study), and whether they exited by dying or being censored (D), VITAL STATUS RECODE. D is a Boolean variable, so D=1 if T=Y, and D=0 if T< Y.

In the discrete time variable case which holds for the SEER data where SURVIVAL MONTHS takes on integer values, the relationship between the hazard function and the survival function is given as follows [14]. Suppose that $a_j < t \le a_{j+1}$ where a_j represents j months. Then

$$S(t) = P(T \ge a_1, T \ge a_2, \cdots, T \ge a_{j+1})$$
(3.3)

$$= P(T \ge a_1)P(T \ge a_2|T \ge a_1) \cdots P(T \ge a_{j+1}|T \ge a_j)$$
 (3.4)

$$= (1 - \lambda_1) \times \dots \times (1 - \lambda_i) \tag{3.5}$$

$$= \prod_{k:a_k < t} (1 - \lambda_k) \tag{3.6}$$

Treating T is just another covariate is the key to the transformation. Each datapoint in the hidden classification problem is the combination of an \mathbf{X}_i in the original dataset plus some month t, and the classification problem is "did point \mathbf{X}_i die in month t." We will call this new variable D_{it} (newtarget). We can transform our original data set into a new one, with one row for each month that each \mathbf{X}_i is in the sample; train a standard classifier on this new dataset with D_{it} as the target, and derive a survival model from the original dataset. Psuedocode for this transformation is found in section \mathbf{B} .

Explicit examples will help make this transformation clear. The untransformed datapoint represented Table (9) is transformed to the multiple records shown in Table (11). All uncensored data is transformed in this way. All censored data is similarly transformed.

	cs_tumor_size	year_of_birth	survival_months	vital_status_recode_Dead
newindex				
205	60	1951	3	1

Table 9. Example of four columns in an uncensored record in the untransformed dataset.

	cs_tumor_size	year_of_birth	survival_months	vital_status_recode_Dead
newindex				
205	40	1950	3	0

Table 10. Example of four columns in a censored record in the untransformed dataset.

	cs_tumor_size	year_of_birth	month	newtarget
newindex				
205	60	1951	0	0
205	60	1951	1	0
205	60	1951	2	0
205	60	1951	3	1

Table 11. Example of four columns in an uncensored record in the transformed dataset.

	cs_tumor_size	year_of_birth	month	newtarget
newindex				
205	40	1950	0	0
205	40	1950	1	0
205	40	1950	2	0
205	40	1950	3	0

Table 12. Example of four columns in a censored record in the transformed dataset.

The untransformed datapoint represented Table (10) is transformed to the multiple records shown in Table (12).

One obvious side effect of this transformation is that it explodes the data size. For this study, the original, untransformed colon cancer DataFrame has shape (113072, 106), and the total transformed colon cancer DataFrame has shape (4165251, 106). Similarly, the original, untransformed lung cancer DataFrame has shape (177089, 118), and the total transformed lung cancer DataFrame has shape (3079931, 118). The biggest explosion in data size occurred with the breast cancer data. The original, untransformed breast cancer

DataFrame has shape (329949, 70), and the total transformed breast cancer DataFrame has shape (15085711, 70). Training machine learning algorithms on such large datasets, even after splitting into training and testing sets described below, require large RAM. All computations for this study were performed on a Dell XPS 8700 Desktop with 32GB of RAM.

4 Prediction Models

With the datasets transformed as described in section (3.2), we are now able to split them into training and testing sets in the usual manner. The classifier models described in this section are learning the hazard function: given all of the data given in sections (A.2, A.1, A.3), which includes the field months (the months after diagnosis), the models predict the target variable newtarget, which represents the probability of dying in that month, given that the patient represented by the record has survived up to that month. The models learn $\lambda(\mathbf{X}, \mathbf{months})$. This prediction task should not be confused with the regression problem of trying to predict precisely in what month a patient will die. The hazard functions thus learned and predicted are intermediary products; what we are really pursuing are the survival functions for each patient that are derived from the learned and predicted hazard functions. From the resulting hazard functions for each unique patient, we can construct the resulting survival functions as presented in section (B) and Equation (3.6).

In order to evaluate the performance of the learned models, we first construct three binary classifiers corresponding to whether or not a subject survived 6, 12, or 60 months after diagnosis. This is done by iterating over all distinct patient indices in the test set, prediciting the full survival function, and capturing the values corresonding to 6, 12, and 60 months. If the survival function evaluted at 6 months is greater than or equal to .5 for a given subject, then the 6 months binary classifier predicts that that subject will be alive 6 months after diagnosis. Similarly, if the survival function evaluted at 60 months is less than .5, then the 12 months binary classifier predicts that that subject will be dead 12 months after diagnosis. Figure (4) illustrates the method; in this case the 6-month and 12-month classifiers predict survival, while the 60-month classifier predicts expiry.

It is necessary to apply some Boolean filters to the data in order to correctly assess the resulting classifiers, again because of censoring. For example, to construct AUC curves for the 6 month classifier, we restrict ourselves to considering subjects in the test data where either of the following mutually exlusive conditions holds:

```
ullet survival_months >=6~\mathrm{AND} vital_status_recode ==0
```

ullet vital_status_recode ==1

That is, we restrict ourselves to subsets of the data where we know for certain whether or not the subject survived at least 6 months. Similarly for the 12 and 60 months surivival classifiers.




Figure 4. Example of the construction of the binary classifiers for 6, 12, and 60 months survival. A subjects hazard curve $h(\mathbf{X}, t)$ is predicted by the predictions models for times out to 120 months. The survival curve is then readily computed as in section (B). For this example, the 6-month and 12-month classifiers predict survival, while the 60-month classifier predicts expiry.

4.1 Training and Test Partitions

After performing the data transformation adumbrated in section (3.2), it is necessarily to be mindful of how we partition the data into training and testing data. Each subject that was represented by a single row in the original untransformed dataset now potentially is represented by multiple rows in the transformed dataset, and care must be taken to ensure that all of the rows corresponding to a particular subject are either assigned exclusively to the training set or to the testing set. An additional characteristic of this transformed data that requires careful treatment involves balancing. The transformation results in many new records with the target variable newtarget == 0. The training and test sets must be chosen such that the ratio of the number of records with newtarget == 0 to that of the number of records with newtarget == 1 is the same in the training and test datasets. This ratio turns out to be ≈ 396 for the breast cancer data, ≈ 99 for the colon cancer data, and ≈ 22.75 for the lung cancer data.

The models described below are trained to learn the values of newtarget, which is a binary variable: a value of '0' indicating that the subject is still alive at the given month, while a value of '1' indicates that the patient died at that particular value of months. The random forests and neural networks described below are binary classifiers with the target newtarget. Fortunately, both the random forests and neural networks are capable of not

only performing strict class prediction, i.e. predicting whether **newtarget** is '0' or '1', but are also able to predict the *probablity* of **newtarget** being '0' or '1'., and thus learning the hazard function.

Finally, we emphasize the crucial point that features survival_months and vital_status_recode_Dead are dropped from both the training and and testing data, and are replaced with the features months and newtarget, as illustrated in Tables (9, 10, 11, 12). The information of which subjects represent censored data (vital_status_recode_Dead == 0) and which died is retained and recoverable trough the newindex variable and is needed for proper evaluation of the performance metrics; when evaluating AUC curves for the 6, 12, and 60 month binary classifiers, we need to limit the test data to those subjects that we know definitively whether or not they survived 6, 12 or 60 months respectively. This requirement will necessitate the elmination of some of the censored data when computing some of the performance metrics.

4.2 Decision Trees and Random Forests

Decision tree classifiers are attractive models because they can be intrepeted easily. Like the name decision tree suggests, we can think of this model as breaking down our data by making decisions based on asking a series of questions. Based on the features in our training set, the decision tree model learns a series of questions to infer the class labels of the samples.

Random forests have gained huge popularity in applications of machine learning during the last decade due to their good classification performance, scalability, and ease of use. Intuitively, a random forest can be considered as an *ensemble of decision trees*. The idea behind ensemble learning is to combine **weak learners** to build a more robust model, a **strong learner**, that has a better generalization error and is less susceptible to overfitting.

The goal behind **ensemble methods** is to combine different classifiers into a metaclassifier that has a better generalization performance than each individual classifier alone. For example, assuming that we collected predictions from 10 experts, ensemble methods would allow us to strategically combine these predictions by the 10 experts to come up with a prediction that is more accurate and robust than the predictions by each individual expert. The individual decision trees that make an ensemble are called base learners, and as long as the error rate of each base learner is less than .50, the combined random forest will benefit from the affects of combining predictions to achieve a far greater accuracy.

Figure (5) illustrates the power of ensemble methods; the Figure illustrates how the ensemble error rate is much lower than the Base learner error rate, as long as the Base learner error rate is less than 0.5. The Figure illustrates this effect for an ensemble of 500 base learners.

IOBS has chosen to use the Python scikit-learn implementaion of the Random Forest machine learning classifier [15]. Random Forests are frequent winners of the Kaggle machine learning competitions [16]. The model parameters for each cancer type are given in sections (C.1, C.2, C.3).




Figure 5. Illustration of ensemble methods showing how a collection of base learners with poor accuracy can combine to produce an accurate ensemble learner.

4.3 MLP Neural Networks

Neural networks are a biologically-inspired programming paradigm that enable computers to learn from observational data [17]. Deep learning can be understood as a set of algorithms that were developed to train **artificial neural networks** with many layers most efficiently. Neural networks are a hot topic not only in academic research, but also in big technology companies such as Facebook, Microsoft, and Google who invest heavily in artificial neural networks and deep learning research. As of today, complex neural networks powered by deep learning algorithms are considered as state-of-the-art when it comes to complex problem solving such as image and voice recognition. In addition, the pharmaceutical industry recently started to use deep learning techniques for drug discovery and toxicity prediction, and research has shown that these novel techniques substantially exceed the performance of traditional methods for virtual screening [18].

IOBS has chosen to use the neural network implementation Keras developed at MIT. Keras was initially developed as part of the research effort of project ONEIROS (Openended Neuro-Electronic Intelligent Robot Operating System) [19]. Keras is a minimalist, highly modular neural networks library, written in Python and capable of running on top of either TensorFlow or Theano. The model architecture for each cancer type are given in sections (C.4, C.5, C.6). Training a neural network and choosing an appropriate architecture is as much art as science [17], and the search for a good neural network architecture for the lung cancer case was more demanding than for the breast and colon.

Model	6 Months AUC	12 Months AUC	60 Months AUC
Breast RF	.846	.885	.844
Breast NN	.855	.867	.836
Colon RF	.804	.806	.828
Colon NN	.797	.804	.841
Lung RF	.772	.796	.874
Lung NN	.765	.796	.875

Table 13. AUC values for the Random Forest and Neural Networks model binary classifiers derived from the full survival curve predictions; see text for details.

5 Results

5.1 Performance Metrics

The AUC scores for each of the 18 different binary classifiers are listed in Table (13). We emphasize the treatment explained in section (4) concering the correct treatment of the censored test data when evaluating performance metrics. Namely, when computing the AUC for the 12 month survival curve classifiers, we restrict the test data subjects to those that in the untransformed data set that satisfy either of the following mutually exlusive conditions:

- ullet survival_months $>=12~\mathrm{AND}$ vital_status_recode ==0
- ullet vivtal_status_recode ==1

We limit evaluation data to subsets of the data where we know for certain whether or not the subject survived at least 12 months. Similar considerations apply to the 12 and 60 months AUC calculations. The lowest AUC in Table (13) is .765, corresponding to the lung neural network model predictions for 6 months survival, while the highest AUC in Table (13) is .885, corresponding to the breast random forest model predictions for 12 months survival.

5.2 Model Agreement

TO DO: Check if comorbidites are contributing to the outliers in the agreement boxplots that follow. Could mesh with the prevous work [5].

An additional means of validating the predictions of these models is by comparing their predictions to each other for the same set of input data. Table (14) shows the strong agreement between the random forest and neural network classifiers for each cancer type. Python code showing how the values in Table (14) are computed is available in the files NewPatientBreastCF.html, NewPatientColonCF.html, and NewPatientLung.html in the GitHub repository containing supplemental matierial for this study [13]. This table is computed as follows. For each cancer type (breast,colon, and lung), do the following:

Cancer Type	% agreement 6 months	% agreement 12 months	% agreement 60 months
Colon	.981	.971	.915
Breast	.994	.984	.938
Lung	.861	.883	.900

Table 14. Percentage agreement for the Random Forest and Neural Network classifiers for 6, 12, and 60 month survival predictions on the test data for each cancer type.

- use the corresponding Random Forest and Neural Network models to compute the survival curves for all of the test subjects
- extract the values of the survival curve evaluted for 6, 12, and 60 months for both both models
- if both models predict less than .5 or both models predict greater than or equal to .5, that counts as agreement
- otherwise, the models disagree

This high level of agreement between two models lends confidence to the notion that they have both learned from the training data and are generalizing well. Figures (8, 7, 9) show box plots of the value of the random forest prediction subtracted from the neural network prediction.

6 Survival Curve Prediction Apps

CF this guy http://kmplot.com/analysis/index.php?p=service&cancer=lung

Below is a list of some web applications developed by IOBS. For each of the cancer types (colon, breast, lung, and prostate), a model has been developed using random forests and one using neural networks. The models were evaluted using the AUC (Area Under Curve) performance evaluation metric on test data (data not used in the training of the models), typically achieving AUC scores $\approx .8$, as shown in Table (13).⁵

- 1. breast cancer
 - (a) random forest: http://ming-cancer.herokuapp.com/
 - (b) neural network: http://breastcancer-neuralnetwork.herokuapp.com/
- 2. lung cancer
 - (a) random forest: http://lung-cancer.herokuapp.com/
 - (b) neural network: http://lungnn.herokuapp.com/
- 3. colon cancer
 - (a) random forest: http://colon-cancer.herokuapp.com/
 - (b) neural network: http://coloncancernn.herokuapp.com/

⁵"AUC | Kaggle," Kaggle Website, https://www.kaggle.com/wiki/AUC, accessed 11 Jan 2016.

4. prostate cancer

(a) random forest: http://prostate-cancer.herokuapp.com/

These machine learning models are used to predict survival curves for a given set of input data. The resulting surival curves predict the probability that a patient with the given input data will survive at least up to month x. For example, using the Colon Cancer neural network app, and inputing the values listed in Table (15) results in the survival curve depicted in Figure (10); the predicted probabilities of living at least 6, 12, and 60 months are .89, .83, and .50, respectively.

Variable	Value
What is the tumor size (mm)	300
What is the patient's address?	boston massachusetts
Grade	moderately differentiated
Histology	adenomas and adenocarcinomas
Laterality	not a paired site
Martial Status at Dx	Single, never married
Month of Diagnosis	Jan
How many primaries	1
Race_ethnicity	\mathbf{W} hite
$seer_historic_stage_a$	Regional
Gender	Male
$spanish_hispanic_origin$	${ m Non\text{-}spanish/Non\text{-}hispanic}$
Year of Birth	1940
Year of Diagnosis	2010

Table 15. Example input data to the Colon Cancer neural network app.

Changing the data in Table (15) so that the address field is changed from Boston, Massachusetts to Denver, Colorado but keeping all other variables are unchanged results in the predicted probabilities of living at least 6, 12, and 60 months: .945, .902, .665. Behind the scenes, the apps use the input to the address field to make a call to the Google Maps API to convert the address into a latitude, longitude and elevation. These probablities are noticeably higher and reflect the documented effects of both longitude and elevation on cancer treatment and prognosis in the United States [20].

7 Further Directions

Discussion of causality. A certain Marital status is not a "cause" of a better prognosis; c.f. Simpson's Paradox. Implementation of Judea Pearl's Causality Calculus.

The leap from observation to causality can be hazardous, however, if not analyzed correctly⁶. IOBS is looking into making these conclusions drawn from evidence-based, machine learning models more rigorous by firmly vetting them within the cutting-edge methods of Causality Calculus as pioneered by Judea Pearl.⁷

A Selected Features

In this Appendix we explicitly list the features chosen for each of the Colon, Breast and Lung cancer predictive models. For each cancer type, the features chosen for the random forest and neural network models were the same, so as to be best able to compare the two models. IPython notebooks explicitly providing all code, as well as html versions of the notebooks, are available from a GitHub repository providing supplemental material for thus study [13].

A.1 Colon Cancer Feature Selection

The feature set used as input into both the Random Forest and Neural Network models, after the transformation described in section (3.2) is given below and also available in full detail in the file NewPatientColonML.html.

- cs_tumor_size
- elevation
- grade cell type not determined
- grade moderately differentiated
- grade poorly differentiated
- grade undifferentiated; anaplastic
- grade well differentiated
- histology recode broad groupings acinar cell neoplasms
- histology recode broad groupings adenomas and adenocarcinomas
- histology recode broad groupings blood vessel tumors
- histology recode broad groupings complex epithelial neoplasms
- histology recode broad groupings complex mixed and stromal neoplasms
- histology recode broad groupings cystic, mucinous and serous neoplasms
- histology recode broad groupings ductal and lobular neoplasms
- histology recode broad groupings epithelial neoplasms, NOS
- histology recode broad groupings fibromatuos neoplasms
- histology recode broad groupings germ cell neoplasms
- histology recode broad groupings lipomatous neplasms
- histology recode broad groupings miscellaneous bone tumors
- histology recode broad groupings myomatous neoplasms

^{6&}quot;Simpson's Paradox," http://www.intuitor.com/statistics/SimpsonsParadox.html, accessed 11 Jan 2016.

⁷Judea Pearl homepage at the University of California, Los Angeles, http://bayes.cs.ucla.edu/jp_home.html, accessed 11 Jan 2016.

- histology recode broad groupings neuroepitheliomatous neoplasms
- histology recode broad groupings nevi and melanomas
- \bullet histology_recode_broad_groupings_paragangliom as and glumus tumors
- histology recode broad groupings soft tissue tumors and sarcomas, NOS
- histology recode broad groupings squamous cell neoplasms
- histology recode broad groupings synovial-like neoplasms
- histology recode broad groupings transistional cell papillomas and carcinomas
- histology recode broad groupings unspecified neoplasms
- lat
- laterality_Left: origin of primary
- laterality_Not a paired site
- laterality Only one side involved, right or left origin unspecified
- laterality_Paired site, but no information concerning laterality; midline tumor
- laterality_Right: origin of primary
- lng
- marital status at dx Divorced
- marital_status_at_dx_Married (including common law)
- marital status at dx Separated
- marital status at dx Single (never married)
- marital status at dx Unknown
- marital status at dx Unmarried or domestic partner
- marital status at dx Widowed
- month_of_diagnosis_Apr
- month of diagnosis Aug
- month_of_diagnosis_Dec
- month of diagnosis Feb
- month of diagnosis Jan
- $\bullet \hspace{0.1cm} \text{month_of_diagnosis_Jul} \\$
- month of diagnosis Jun
- \bullet month_of_diagnosis_Mar
- month of diagnosis May
- \bullet month_of_diagnosis_Nov
- month of diagnosis Oct
- \bullet month_of_diagnosis_Sep
- number of primaries
- race_ethnicity_Amerian Indian, Aleutian, Alaskan Native or Eskimo
- race ethnicity Asian Indian
- race ethnicity Asian Indian or Pakistani
- race ethnicity Black
- race ethnicity Chinese
- race ethnicity Fiji Islander
- race ethnicity Filipino
- race ethnicity Guamanian

- race ethnicity Hawaiian
- race ethnicity Hmong
- \bullet race_ethnicity_Japanese
- race ethnicity Kampuchean
- race ethnicity Korean
- race_ethnicity_Laotian
- race ethnicity Melanesian
- \bullet race_ethnicity_Micronesian
- race_ethnicity_New Guinean
- \bullet race_ethnicity_Other
- race ethnicity Other Asian
- race_ethnicity_Pacific Islander
- race ethnicity Pakistani
- race_ethnicity_Polynesian
- race_ethnicity_Samoan
- race ethnicity Thai
- race_ethnicity_Tongan
- race ethnicity Unknown
- race ethnicity Vietnamese
- race ethnicity White
- seer historic stage a Distant
- seer_historic_stage_a_In situ
- seer historic stage a Localized
- seer historic stage a Regional
- seer_historic_stage_a_Unstaged
- \bullet sex Female
- spanish hispanic origin Cuban
- spanish hispanic origin Dominican Republic
- spanish hispanic origin Mexican
- spanish hispanic origin Non-Spanish/Non-hispanic
- spanish_hispanic_origin_Other specified Spanish/Hispanic origin (excludes Dominican Repuclic)
- spanish hispanic origin Puerto Rican
- spanish_hispanic_origin_South or Central American (except Brazil)
- spanish hispanic origin Spanish surname only
- spanish hispanic origin Spanish, NOS; Hispanic, NOS; Latino, NOS
- spanish hispanic origin_Uknown whether Spanish/Hispanic or not
- year of birth
- year of diagnosis
- \bullet month

and newtarget is the target variable, indicating whether or not the subject died in month given by the value of the month variable.

A.2 Lung Cancer Feature Selection

The feature set used as input into both the Random Forest and Neural Network models, after the transformation described in section (3.2) is given below and also available in full detail in the file NewPatientLungML.html.

- cs tumor size
- elevation
- grade cell type not determined
- grade moderately differentiated
- grade poorly differentiated
- grade undifferentiated; anaplastic
- grade_well differentiated
- histology_recode_broad_groupings_acinar cell neoplasms
- histology_recode_broad_groupings_adenomas and adenocarcinomas
- histology_recode_broad_groupings_blood vessel tumors
- histology recode broad groupings complex epithelial neoplasms
- histology recode broad groupings complex mixed and stromal neoplasms
- histology_recode_broad_groupings_cystic, mucinous and serous neoplasms
- histology recode broad groupings ductal and lobular neoplasms
- histology recode broad groupings epithelial neoplasms, NOS
- histology recode broad groupings fibroepithelial neoplasms
- histology recode broad groupings fibromatuos neoplasms
- histology recode broad groupings germ cell neoplasms
- histology recode broad groupings gliomas
- histology_recode_broad_groupings_granular cell tumors & alveolar soft part sarcomas
- histology recode broad groupings lipomatous neplasms
- histology recode broad groupings miscellaneous bone tumors
- histology recode broad groupings miscellaneous tumors
- histology recode broad groupings mucoepidermoid neoplasms
- histology recode broad groupings myomatous neoplasms
- $\bullet \ histology_recode_broad_groupings_myxomatous\ neoplasms$
- histology recode broad groupings nerve sheath tumors
- $\bullet \ \ histology_recode_broad_groupings_neuroepitheliomatous\ neoplasms$
- histology recode broad groupings nevi and melanomas
- histology_recode_broad_groupings_osseous and chondromatous neoplasms
- histology recode broad groupings paragangliomas and glumus tumors
- histology recode broad groupings soft tissue tumors and sarcomas, NOS
- histology recode broad groupings squamous cell neoplasms
- histology recode broad groupings synovial-like neoplasms
- histology recode broad groupings thymic epithelial neoplasms
- histology recode broad groupings transistional cell papillomas and carcinomas
- histology recode broad groupings trophoblastic neoplasms

- histology recode broad groupings unspecified neoplasms
- lat
- laterality_Bilateral involvement, lateral origin unknown; stated to be single primary
- laterality Left: origin of primary
- laterality Not a paired site
- laterality_Only one side involved, right or left origin unspecified
- laterality Paired site, but no information concerning laterality; midline tumor
- laterality_Right: origin of primary
- lng
- marital status at dx Divorced
- marital status at dx Married (including common law)
- marital status at dx Separated
- marital_status_at_dx_Single (never married)
- \bullet marital_status_at_dx_Unknown
- marital_status_at_dx_Unmarried or domestic partner
- \bullet marital_status_at_dx_Widowed
- month_of_diagnosis_Apr
- month of diagnosis Aug
- month of diagnosis Dec
- month of diagnosis Feb
- ullet month_of_diagnosis_Jan
- $\bullet \hspace{0.1cm} \text{month_of_diagnosis_Jul} \\$
- month_of_diagnosis_Jun
- month of diagnosis Mar
- month_of_diagnosis_May
- month of diagnosis Nov
- month of diagnosis Oct
- month of diagnosis Sep
- number of primaries
- race ethnicity Amerian Indian, Aleutian, Alaskan Native or Eskimo
- race ethnicity Asian Indian
- race ethnicity Asian Indian or Pakistani
- race ethnicity Black
- race_ethnicity_Chamorran
- race ethnicity Chinese
- race_ethnicity_Fiji Islander
- race ethnicity Filipino
- race_ethnicity_Guamanian
- $\bullet \ \ {\rm race_ethnicity_Hawaiian}$
- race ethnicity Hmong
- race ethnicity Japanese
- race ethnicity Kampuchean
- race_ethnicity Korean

- race ethnicity Laotian
- race ethnicity Melanesian
- race ethnicity Micronesian
- race ethnicity New Guinean
- race ethnicity Other
- race ethnicity Other Asian
- race ethnicity Pacific Islander
- race_ethnicity_Pakistani
- race ethnicity Polynesian
- race ethnicity Samoan
- \bullet race_ethnicity_Thai
- race_ethnicity_Tongan
- race_ethnicity_Unknown
- \bullet race_ethnicity_Vietnamese
- race_ethnicity_White
- seer_historic_stage_a_Distant
- seer historic stage a In situ
- seer historic stage a Localized
- seer historic stage a Regional
- seer historic stage a Unstaged
- sex Female
- spanish hispanic origin Cuban
- spanish hispanic origin Dominican Republic
- spanish hispanic origin Mexican
- spanish_hispanic_origin_Non-Spanish/Non-hispanic
- spanish_hispanic_origin_Other specified Spanish/Hispanic origin (excludes Dominican Repuclic)
- spanish hispanic origin Puerto Rican
- spanish hispanic origin South or Central American (except Brazil)
- spanish hispanic origin Spanish surname only
- spanish_hispanic_origin_Spanish, NOS; Hispanic, NOS; Latino, NOS
- spanish hispanic origin Uknown whether Spanish/Hispanic or not
- year of birth
- \bullet year_of_diagnosis
- month

and newtarget is the target variable, indicating whether or not the subject died in month given by the value of the month variable.

A.3 Breast Cancer Feature Selection

The feature set used as input into both the Random Forest and Neural Network models, after the transformation described in section (3.2) is given below and also available in full detail in the file NewPatientBreastML.html.

- cs tumor size
- elevation
- grade moderately differentiated
- grade poorly differentiated
- grade ndifferentiated; anaplastic
- grade well differentiated
- histology recode broad groupings adenomas and adenocarcinomas
- histology_recode_broad_groupings_adnexal and skin appendage neoplasms
- histology recode broad groupings basal cell neoplasms
- $\bullet \ histology_recode_broad_groupings_complex\ epithelial\ neoplasms$
- \bullet histology_recode_broad_groupings_cystic, mucinous and serous neoplasms
- histology_recode_broad_groupings_ductal and lobular neoplasms
- histology_recode_broad_groupings_epithelial neoplasms, NOS
- histology_recode_broad_groupings_nerve sheath tumors
- histology_recode_broad_groupings_unspecified neoplasms
- lat
- laterality_Bilateral involvement, lateral origin unknown; stated to be single primary
- laterality Paired site, but no information concerning laterality; midline tumor
- laterality Right: origin of primary
- lng
- \bullet marital_stats_at_dx_Divorced
- marital stats at dx Married (inclding common law)
- \bullet marital_stats_at_dx_Separated
- marital stats at dx Single (never married)
- marital_stats_at_dx_Unknown
- marital_stats_at_dx_Unmarried or domestic partner
- marital stats at dx Widowed
- month of diagnosis Apr
- month of diagnosis Aug
- month of diagnosis Dec
- month of diagnosis Feb
- ullet month_of_diagnosis_Jan
- month of diagnosis Jul
- month_of_diagnosis_Jun
- $\bullet \hspace{0.1cm} \mathrm{month_of_diagnosis_Mar}$
- month_of_diagnosis_May
- month_of_diagnosis_Nov
- month_of_diagnosis_Oct
- month of diagnosis Sep
- race ethnicity Amerian Indian, Aletian, Alaskan Native or Eskimo
- race ethnicity Asian Indian
- race ethnicity Black
- race ethnicity Chinese

- race ethnicity Japanese
- race_ethnicity_Melanesian
- race ethnicity Other
- race ethnicity Other Asian
- race ethnicity Pacific Islander
- race ethnicity Thai
- race ethnicity Unknown
- \bullet race_ethnicity_Vietnamese
- race_ethnicity_White
- \bullet seer_historic_stage_a_Distant
- \bullet seer_historic_stage_a_In sit
- seer historic stage a Localized
- seer_historic_stage_a_Unstaged
- \bullet sex_Female
- spanish_hispanic_origin_Cuban
- spanish hispanic origin Mexican
- spanish_hispanic_origin_Non-Spanish/Non-hispanic
- spanish_hispanic_origin_Other specified Spanish/Hispanic origin (excldes Dominican Republic)
- spanish hispanic origin Spanish surname only
- spanish_hispanic_origin_Spanish, NOS; Hispanic, NOS; Latino, NOS
- year of birth
- year of diagnosis
- month

and newtarget is the target variable, indicating whether or not the subject died in month given by the value of the month variable.

B Pseudocode for the Data Transformation

```
def train(X, T, D)
    // X, T, D are the original dataset
    X' = []
    D' = []

    // the transformation
    for each index i in X:
        for t=1 to T[i]:
            new_D = (0 if t < T[i], else D[i])
            append new_D to D'
            new_X = (X[i], t)
            append new_X to X'</pre>
```

```
return a decision tree trained on (X', D')

def pmf(h, X)
    // X is a single datapoint
    // returns an array A where A[i] = P(Y = i | X)
    A = []
    p_so_far = 1 // this is p(T >= t | X)
    for t = 1 to (the last month where h has any data):
        // h knows p(T = t | T >= t, X), we call this p_cur
        p_cur = h's prediction for (X, t)
        append (p_so_far * p_cur) to A
        p_so_far *= (1 - p_cur)
```

C Model Architecture and Python Code

C.1 Breast Random Forest Model

C.2 Colon Random Forest Model

C.3 Lung Random Forest Model

C.4 Breast Neural Network Model

The architecture of the Keras multilayer perceptron neural network model trained on the breast cancer data is given explicitly below:

```
modelbreast = Sequential()
modelbreast.add(Dense(114, input_shape=(66,) ,init='normal'))
modelbreast.add(Activation('relu'))
modelbreast.add(Dropout(0.05))
```

```
modelbreast.add(Dense(50, init='normal'))
modelbreast.add(Activation('relu'))
modelbreast.add(Dropout(0.05))

modelbreast.add(Dense(36, init='normal'))
modelbreast.add(Activation('relu'))
modelbreast.add(Dropout(0.05))

modelbreast.add(Dense(2, init='normal'))
modelbreast.add(Activation('softmax'))

rms = RMSprop(lr=0.001)

modelbreast.compile(loss='binary_crossentropy', optimizer=rms, class_mode="binary")
```

C.5 Colon Cancer Neural Network Model

and trained with a batch size of 1500 for 200 epochs.

The architecture of the Keras multilayer perceptron neural network model trained on the colon cancer data is given explicitly below:

```
modelcolon = Sequential()
modelcolon.add(Dense(114, input_shape=(102,) ,init='normal'))
modelcolon.add(Activation('relu'))
modelcolon.add(Dropout(0.05))
modelcolon.add(Dense(50, init='normal'))
modelcolon.add(Activation('relu'))
modelcolon.add(Dropout(0.05))

modelcolon.add(Dense(35, init='normal'))
modelcolon.add(Activation('relu'))
modelcolon.add(Dropout(0.05))

modelcolon.add(Dense(2, init='normal'))
modelcolon.add(Dense(2, init='normal'))
modelcolon.add(Activation('softmax'))

rms = RMSprop(lr=0.001)

modelcolon.compile(loss='binary_crossentropy', optimizer=rms, class_mode="binary")
```

and trained with a batch size of 1500 for 200 epochs.

C.6 Lung Cancer Neural Network Model

The architecture of the Keras multilayer perceptron neural network model trained on the lung cancer data is given explicitly below:

```
modellung = Sequential()
modellung.add(Dense(114, input_shape=(114,) ,init='normal'))
modellung.add(Activation('relu'))
modellung.add(Dropout(0.1))
modellung.add(Dense(80, init='normal'))
modellung.add(Activation('relu'))
modellung.add(Dropout(0.1))
modellung.add(Dense(40, init='normal'))
modellung.add(Activation('relu'))
modellung.add(Dropout(0.1))

modellung.add(Dropout(0.1))

modellung.add(Activation('softmax'))

rms = RMSprop(lr=0.001)
modellung.compile(loss='binary_crossentropy', optimizer=rms, class_mode="binary")
```

and trained with a batch size of 2000 for 50 epochs.

Acknowledgments

This is the most common positions for acknowledgments. A macro is available to maintain the same layout and spelling of the heading.

Note added. This is also a good position for notes added after the paper has been written.

References

- [1] Sebastian Raschka, Python Machine Learning Essentials. Packt Publishing, 2015.
- [2] Cam Davidson-Pilon, "Quickstart lifelines 0.8.0.1 documentation." http://lifelines.readthedocs.org/en/latest/Quickstart.html, 2016 (accessed 14 Jan 2016).

- [3] National Cancer Institute, the Surveillance, Epidemiology, and End Results Program, "About the SEER Program SEER." http://seer.cancer.gov/about, 2016 (accessed 14 Jan 2016).
- [4] Shin, Hyunjung and Nam, Yonghyun, "A coupling approach of a predictor and a descriptor for breast cancer prognosis," BMC MEDICAL GENOMICS, vol. 7, MAY 8 2014. 3rd Annual Translational Bioinformatics Conference (TBC) / ISCB-Asia, Seoul, SOUTH KOREA, OCT 02-04, 2013.
- [5] Zolbanin, Hamed Majidi and Delen, Dursun and Zadeh, Amir Hassan, "Predicting overall survivability in comorbidity of cancers: A data mining approach," *DECISION SUPPORT SYSTEMS*, vol. 74, pp. 150–161, JUN 2015.
- [6] Ben Kuhn, "Decision trees for survival analysis." http://www.benkuhn.net/survival-trees, 2016 (accessed 14 Jan 2016).
- [7] National Cancer Institute, the Surveillance, Epidemiology, and End Results Program, "Documentation for ASCII Text Data Files SEER Datasets." http://seer.cancer.gov/data/documentation.html, 2016 (accessed 15 Jan 2016).
- [8] Michael Bowles, Machine Learning in Python: Essential Techniques for Predictive Analysis. Wiley, 2015.
- [9] Allen Downey, Think Stats. O'Reilly Media, 2014.
- [10] United States Census Bureau, "2010 fips code files for counties geography u.s. census bureau." https://www.census.gov/geo/reference/codes/cou.html, 2016 (accessed 18 Jan 2016).
- [11] Google Developers, "The google maps geocoding api | google maps geocoding api | google developers." https://developers.google.com/maps/documentation/geocoding/intro, 2016 (accessed 18 Jan 2016).
- [12] Google Developers, "The google maps elevation api | google maps elevation api | google developers." https://developers.google.com/maps/documentation/elevation/intro?hl=en, 2016 (accessed 18 Jan 2016).
- [13] IOBS, "Supplemental material | paperdata." https://github.com/doolingdavid/PAPERDATA.git, 2016 (accessed 18 Jan 2016.
- [14] Northeastern Illinois Chapter, American Statistical Association, "Survival analysis: Introduction." http://www.amstat.org/chapters/northeasternillinois/pastevents/presentations/summer05_Ibrahim_J.pdf, 2005 (accessed 27 Jan 2016).
- [15] scikit-learn developers, "3.2.4.3.1. sklearn.ensemble.randomforestclassifier." http://scikit-learn.org/stable/modules/generated/sklearn.ensemble. RandomForestClassifier.html, 2014 (accessed 25 Jan 2016).
- [16] Kaggle Inc., "Random forests | kaggle." https://www.kaggle.com/wiki/RandomForests, 2015 (accessed 25 Jan 2016.
- [17] Michael Nielsen, "Neural networks and deep learning." http://neuralnetworksanddeeplearning.com/, Jan 2016 (accessed 25 Jan 2016).
- [18] T. Unterthiner, A. Mayr, G. Klambauer, and S. Hochreiter, "Toxicity prediction using deep learning." http://arxiv.org/abs/1503.01445, 4 Mar 2015 (accessed 25 Jan 2016).
- [19] François Chollet, "Keras documentation." http://keras.io/, 2015 (accessed 25 Jan 2016).

[20] Kai Porter, KOB Eyewitness News 4, "Study links higher elevation with lower lung cancer risk." http://www.kob.com/article/stories/s4029233.shtml#.VqlUafkrJhF, 26 Jan 2016 (accessed 27 Jan 2016).




Figure 6. The top levels of a decision tree trained on the Lung Cancer training data.




Figure 7. Box plots showing the distributions of the signed difference between the MLP model's prediction for the probability of surviving 6 months and the Random Forest model's prediction of the same quantity for breast cancer. The plot shows the same quantity for the 12 and 60 months classifiers. It is apparent from the figures that the outliers are due to the neural network models predicting higher survival probablitlies than the random forest for some few cases. These differences were evaluated for the 3300 test patients in the breast cancer data.



Figure 8. Box plots showing the distributions of the signed difference between the MLP model's prediction for the probability of surviving 6 months and the Random Forest model's prediction of the same quantity for colon cancer. The plot shows the same quantity for the 12 and 60 months classifiers. It is apparent from the figures that the outliers are due to the neural network models predicting higher survival probablitlies than the random forest for some few cases. These differences were evaluated for the 5654 test patients in the colon cancer data.



Figure 9. Box plots showing the distributions of the signed difference between the MLP model's prediction for the probability of surviving 6 months and the Random Forest model's prediction of the same quantity for lung cancer. The plot shows the same quantity for the 12 and 60 months classifiers. These differences were evaluated for the 5654 test patients in the colon cancer data. The Interquartile Ranges for lung cancer are visibly larger than those for breast cancer and colon cancer shown in fig 7 and fig 8.

Colon Cancer Survival Curve Prediction

Prediction:

- 1. Probability of Surviving 6 months is 0.897
- 2. Probablility of Surviving 12 months is 0.831
- 3. Probability of Surviving 60 months is 0.504

Predicted Survival Curve from Model



Figure 10. Colon Cancer Survival Curve predicted from the data in Table (15) using the neural network web app http://coloncancer.herokuapp.com/.